FR941013-2-00069 FR941013-2-00055 Food and Drug Administration Conference on FDA-Regulated Products and Pregnant Women; Notice of Public Meeting AGENCY: Food and Drug Administration, HHS. ACTION: Notice of public meeting. SUMMARY: The Food and Drug Administration (FDA) is announcing that the Office of Women's Health, FDA, in cooperation with the Office on Women's Health, Public Health Service; the National Institute of Child Health and Human Development, and the Office of Research on Women's Health, National Institutes of Health; and the Centers for Disease Control and Prevention, is sponsoring a public meeting to gather consumers and representatives from academia, industry, and government to discuss the scientific, legal, and ethical issues associated with testing FDA-regulated products in pregnant women. DATES: The public meeting will be held on Monday, November 7 and Tuesday, November 8, 1994, from 8 a.m. to 5:30 p.m. Registration is recommended by October 26, 1994. An opportunity for public comment is planned on November 7, 1994, from 1:30 p.m. to 2:30 p.m. Submit written notices of participation by October 31, 1994. ADDRESSES: The public meeting will be held at the Hyatt Regency Crystal City Hotel, 2799 Jefferson Davis Hwy., Arlington, VA 22202, 703&hyph;418&hyph;1234. Those persons interested in attending the conference should return registration forms by mail to Michelle Priester, KRA Corp., 1010 Wayne Ave., suite 850, Silver Spring, MD 20910, 301&hyph;495&hyph;1591, FAX 301&hyph;495&hyph;9410. Participants who wish to speak during the public comment session should send name, affiliation, address, and phone number to the contact person listed below. FOR FURTHER INFORMATION CONTACT: Mary C. Gross or Elyse I. Summers, Food and Drug Administration, Office of External Affairs (HF&hyph;24), 5600 Fishers Lane, Rockville, MD 20857, 301&hyph;443&hyph;3390. SUPPLEMENTARY INFORMATION: The meeting will include discussions on: (1) The scope of the use of and the need for medical intervention in pregnancy, (2) the extent to which the physiologic changes of pregnancy alter the metabolism of drugs in pregnant women, (3) the application of scientific, legal, and ethical concepts that apply to clinical trials in pregnant women, and (4) strategies to promote research and collection of information on the use of drugs, biologics, and devices in pregnant women and their effects on the fetus. Dated: October 6, 1994. William K. Hubbard, Interim Deputy Commissioner for Policy. [FR Doc. 94&hyph;25298 Filed 10&hyph;12&hyph;94; 8:45 am] BILLING CODE 4160&hyph;01&hyph;F
